BioSpace News Archive

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.

Pappas Capital, a leading investor in early-stage life sciences companies, has appointed Karen LeVert as Venture Partner to help lead the expansion of the firm’s Specialized Fund Management business, with a focus on identifying attractive investment opportunities in agricultural and other related technologies.

RauCon has now introduced limits to the number of participants of its euroPLX and asiaPLX Pharma Partnering Conferences in order to increase their value for the individual participant.

Quest plans to standardize its immunoassay testing across 19 core laboratories, including a new flagship lab in Clifton, New Jersey with Atellica Solution and automation

Sensorion, a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces it will attend and present at the LSX World Congress 2020, held February 4-5 in London.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., has been appointed President and Chief Executive Officer with effect from February 1, 2020.

KARL STORZ, the leading endoscopy manufacturer, and VirtaMed, world leader in medical training simulation, introduce a novel mixed reality simulator bringing innovation to laparoscopic skills training.

Teva Pharmaceutical Industries Ltd. announced positive results from two Phase 2/3 trials evaluating AJOVY® in patients in Japan. AJOVY is under development in Japan by Otsuka Pharmaceutical Co., Ltd. as part of a May 2017 exclusive license agreement for development and sales of AJOVY in Japan.

License agreement to utilise Affimer proteins in next generation cell and gene therapies

Galecto, Inc., a leading developer of novel treatments for fibrosis and cancer, announces the appointment of the highly experienced industry leader Bertil Lindmark as Chief Medical Officer per February 1, 2020.